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Abstract
Background: Buruli ulcer (BU) is an emerging infectious disease caused by Mycobacterium ulcerans that can result in
extensive necrotizing cutaneous lesions due to the cytotoxic exotoxin mycolactone. There is no specific vaccine against BU
but reports show some degree of cross-reactive protection conferred by M. bovis BCG immunization. Alternatively, an M.
ulcerans-specific immunization could be a better preventive strategy.
Methodology/Principal Findings: In this study, we used the mouse model to characterize the histological and cytokine
profiles triggered by vaccination with either BCG or mycolactone-negative M. ulcerans, followed by footpad infection with
virulent M. ulcerans. We observed that BCG vaccination significantly delayed the onset of M. ulcerans growth and footpad
swelling through the induction of an earlier and sustained IFN-c T cell response in the draining lymph node (DLN). BCG
vaccination also resulted in cell-mediated immunity (CMI) in M. ulcerans-infected footpads, given the predominance of a
chronic mononuclear infiltrate positive for iNOS, as well as increased and sustained levels of IFN-c and TNF. No significant IL-
4, IL-17 or IL-10 responses were detected in the footpad or the DLN, in either infected or vaccinated mice. Despite this
protective Th1 response, BCG vaccination did not avoid the later progression of M. ulcerans infection, regardless of
challenge dose. Immunization with mycolactone-deficient M. ulcerans also significantly delayed the progression of footpad
infection, swelling and ulceration, but ultimately M. ulcerans pathogenic mechanisms prevailed.
Conclusions/Significance: The delay in the emergence of pathology observed in vaccinated mice emphasizes the relevance
of protective Th1 recall responses against M. ulcerans. In future studies it will be important to determine how the transient
CMI induced by vaccination is compromised.
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Introduction
Buruli ulcer (BU), a neglected tropical disease caused by
infection with Mycobacterium ulcerans, initially starts off as a
nonulcerative cutaneous lesion that can eventually progress into
an ulcer if left untreated. BU lesions are mainly due to the
cytotoxic properties of the toxin secreted by M. ulcerans, known as
mycolactone [1].
BU has become an emerging health problem in many endemic
countries and the escalating morbidity rate has an overwhelming
socioeconomic burden on the affected populations [2]. BU mainly
affects rural populations with limited geographic and financial
access to health services. As a result, medical-care seeking is
delayed until advanced clinical forms of the disease are presented,
including extensive skin destruction, multifocal lesions, and bone
involvement [3,4,5,6].
Currently, there is no vaccine against M. ulcerans infection and
the classical approach for BU treatment has been surgical,
involving wide excision of necrotic areas and surrounding healthy
tissues [7,8,9]. Recently, the World Health Organization has
recommended the use of rifampicin and streptomycin during an 8-
week period to minimize the extent of surgery and decrease the
recurrence rate [10]. Despite the progress made in early detection
and treatment of BU, an efficient vaccine would be the best
approach for the control of this devastating infectious disease.
As previously discussed, despite the production of the
mycolactone exotoxin, M. ulcerans behaves like other pathogenic
mycobacteria and has been shown to induce cell-mediated
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immunity (CMI) [11,12,13]. Moreover, efficient differentiation/
proliferation of mycobacteria-specific T cells occurs in the draining
lymph node (DLN) of M. ulcerans-infected mice and these effector T
cells were found to be recruited to the infectious focus [13], where
they can mediate bacterial control by enhancing macrophage
antimicrobial mechanisms through the secretion of IFN-c [14].
However, despite the early development of T cell immunity in
mouse experimental infections, the host response is not sufficient
to inhibit the proliferation of highly virulent M. ulcerans strains
[13]. The associated increase in bacterial loads and consequent
mycolactone build-up results in the destruction of cells recruited to
the infection focus [13,15], inhibition of the early IFN-c-
dependent activation of macrophages [14], and tissue necrosis as
well as in destruction of the DLN itself [13], impairing therefore a
sustained protective immune response.
The above mentioned findings suggest that vaccination protocols
triggering a heightened specific CMI response could play a role in
BU prevention. In line with this rationale, both experimental studies
and clinical trials are consistent with BCG vaccination conferring a
significant, although transient, protection against BU lesions
[16,17,18,19,20,21,22,23]. It has also been suggested that homol-
ogous vaccination inducing M. ulcerans specific immune responses,
could elicit a more appropriate/prolonged protective immunity
against M. ulcerans infection [21,23].
Therefore, unraveling protective immunological mechanisms
against M. ulcerans induced by immunization with mycobacterial
antigens is necessary for the development of improved vaccination
strategies. In the present study we characterized the dynamics of
the local and DLN immune responses of mice previously
immunized with BCG or with a mycolactone-negative strain of
M. ulcerans and later infected with a highly virulent strain of M.
ulcerans.
Methods
Bacteria
M. bovis BCG Pasteur was obtained from the Trudeau Institute
Mycobacterium collection and grown in Proskauer Beck medium
containing 0.05% Tween 80 to mid-log phase and frozen in aliquots
at 280uC. M. ulcerans strains were selected from the Institute of
Tropical Medicine (ITM) collection in Antwerp, Belgium. M.
ulcerans 5114 is a mycolactone-negative strain due to repeated sub-
culturing, leading to the spontaneous loss of MUP038 encoding the
type II thioesterase, the acyltransferase domain of module 5 in mlsA1
and the acyltransferase domain of modules 1 and 2 in mlsB, genes
that are involved in the synthesis of mycolactone [24,25]. M. ulcerans
strain 98–912 is described to be highly virulent for mice [15] and
produces mycolactone type D [26]. The isolates were grown on
Middlebrook 7H9 medium (Becton, Dickinson and Company) with
1.5% of agar at 32uC for approximately 6–8 weeks. For the
preparation of the inoculum, M. ulcerans was recovered, diluted in
phosphate-buffered saline (PBS) to a final concentration of 1 mg/ml
and vortexed using glass beads.
Immunization and infection protocol
Eight-week-old female BALB/c mice were obtained from
Charles River (Barcelona, Spain) and were housed in specific
pathogen free conditions with food and water ad libitum. Mice were
either not vaccinated or vaccinated with a subcutaneous injection
of 5–6 log10 CFU of M. bovis BCG or M. ulcerans 5114, two months
before M. ulcerans 98–912 infection. Infection was carried out in
the left hind footpad with 0.03 ml of M. ulcerans suspension
containing either 4 log10 or 2 log10 CFU, as indicated. The right
hind footpad was used as a control. Footpad swelling was
monitored throughout the experimental infection by using a
caliper to measure the diameter of the frontal area of the footpad.
The time to develop relevant footpad swelling, which was
considered to be at 2.60 mm, was shown by Kaplan-Meier
analysis. After emergence of swelling, mice from all groups
progressed to ulceration of the footpad. For ethical reasons, mice
were sacrificed upon onset of footpad ulceration.
Flow Cytometry
For intracellular staining, single cell suspensions of the popliteal
lymph nodes were stimulated with 50 ng/ml of Phorbol Myristate
Acetate (PMA) and 500 ng/ml of ionomycin in the presence of
10 ug/ml of Brefeldin A for 4 h at 37uC with 5% CO2. After this
incubation period, cells were fixed and permeabilized. The presence
of intracellular IFN-c was determined by using anti-IFN-c (clone
XMG 1.2, BD Pharmingen). Cells were further labeled with a
combinations of fluorochrome-labeled monoclonal antibodies specific
for CD3 (clone 145-2C11), CD19 (clone 1D3), CD4 (clone RM4-5)
or CD8 (clone 53–6.7). Cells were analysed using CELLQuest
software on a Becton Dickinson FACSCalibur flow cytometer.
Extraction of cells from infected footpads
Infected footpads were collected and incubated in 125 U/ml
collagenase XI (Sigma-Aldrich) diluted in DMEM (Gibco), for 2 h
at 37uC. Each footpad was filtered through a 40 mm nylon cell
strainer and washed with DMEM supplemented with 10% heat-
inactivated fetal bovine serum (Sigma-Aldrich).
Bacterial load determination
Infected footpads were excised, individually homogenized and
diluted in 2 ml of PBS. The supernatant was recovered and
decontaminated with 3 ml of sterile HCl 1M supplemented with
0,001% phenol red. After an incubation period of 15 min at room
temperature the suspension was neutralized with sterile NaOH
1M and centrifuged for 20 min. The supernatant was discarded
and the pellet resuspended in PBS. Serial dilutions of the
suspension were plated on nutrient 7H9 agar. Bacterial colony
formation was counted after 6–8 weeks of incubation at 32uC.
Real Time PCR
Cell suspensions from the infected footpad were frozen in
TRIzol reagent (Invitrogen), and total RNA was extracted
according to the manufacturer’s protocol. Reverse transcription
was done with whole RNA using SuperScript II (Invitrogen) and
Oligo(dT) (Invitrogen) according to the manufacturer’s instruc-
tions. cDNA was amplified and the Biorad C1000 real-time PCR
was used for quantification of Ubiquitin (UBQ), IFN-c, IL-4, IL-
10, IL-17, TNF, and MIP2 mRNA with Sybr Green (Qiagen).
The primer sequences were designed and synthesized by TIB
MolBiol and were as follows: UBQ forward, TGG CTA TTA
ATT ATT CGG TCT GCA T; UBQ reverse, GCA AGT GGC
TAG AGT GCA GAG TAA; IFN-c forward TGG CAA AAG
GAT GGT GAC ATG; IFN-c reverse GAC TCC TTT TCC
GCT TCC TGA; IL-4 forward, CTC ATG GAG CTG CAG
AGA CTC TT; IL-4 reverse, CAT TCA TGG TGC AGC TTA
TCG A; IL-10 forward, TTT GAA TTC CCT GGG TGA GAA;
IL-10 reverse, GCT CCA CTG CCT TGC TCT TAT T; IL-17
forward, CTC AGA CTA CCT CAA CCG TTC CA; IL-17
reverse, TTC CCT CCG CAT TGA CAC A; TNF forward,
GCC ACC ACG CTC TTC TGT CT; TNF reverse, TGA GGG
TCT GGG CCA TAG AAC; MIP2 forward, CTC AGT GCT
GCA CTG GT; and MIP2 reverse, AGA GTG GCT ATG ACT
TCT GTC T.
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Histological studies
Mouse popliteal lymph nodes and footpads were harvested,
fixed in buffered formalin and embedded in paraffin. Light-
microscopy studies were performed on tissue sections stained with
hematoxylin and eosin (HE) or Ziehl-Neelsen (ZN). For immuno-
fluorescence staining, tissue sections were deparaffinised and
hydrated. Antigen retrieval was performed with Citrate Buffer
(Lab Vision Corporation) at 96uC for 20 min. Unspecific binding
was prevented by incubating with 5% FBS in PBS with 0,1%
Tween 20 and Triton X 100 (Sigma-Aldrich) for 1 h at room
temperature, after which purified rabbit polyclonal anti-NOS2 (N-
20) (Santa Cruz Biotechnology) was added to the section at a
concentration of 1:100 followed by overnight incubation at 4uC.
Goat anti-rabbit AlexaFluor 568 secondary antibody (Molecular
Probes) was added at a concentration of 1:500 in blocking solution
for 1 hour at room temperature. DAPI (4¢,6-diamido-2-pheny-
lindole hydrochloride, Molecular Probes) was used to detect
nuclei. Images were obtained with an Olympus BX61 microscope.
Statistical analysis
Differences between the means of experimental groups were
analyzed with the two-tailed Student’s t-test. Differences with a P
value#0.05 were considered significant.
Ethics Statement
This study was approved by the Portuguese national authority
for animal experimentation Direcc¸a˜o Geral de Veterina´ria (ID:
DGV 594 from 1st June 2010). Animals were kept and handled in
accordance with the guidelines for the care and handling of
laboratory animals in the Directive 2010/63/EU of the European
Parliament and of the Council.
Results
Immunization with BCG induces an earlier and stronger
Th1 response in the footpad and the DLN, delaying the
onset of pathology caused by highly virulent M. ulcerans
Understanding the mechanisms underlying the partial protec-
tion conferred by BCG vaccination may provide clues on how to
design new interventions to improve host defensive immunity.
Therefore, mice were immunized or not with BCG and infected
two months later in the footpad with 4 log10 CFU of a highly
virulent strain of M. ulcerans. In the non-vaccinated mouse group,
the median time to develop swelling was 47 days, while in BCG
vaccinated mice it was 142 days (Figure 1A). However, despite
vaccination, footpads of mice of all experimental groups
progressed to ulceration (data not shown). Confirming previous
findings by Tanghe et al [27], prior BCG immunization was
responsible for a reduction in the number of viable bacilli in the
infected tissue, during which macroscopic lesions were absent in
the footpads of BCG-vaccinated mice [18,21,22], with a 4 log10
reduction observed at day 52 post-infection (Figure 1B).
To characterize the type of immune response associated with the
BCG-induced delay of M. ulcerans disease, we carried out a
comparative analysis of cytokine kinetics in footpads. As previously
described, in the footpads of non-immunized M. ulcerans-infected mice
[14], we found an increase in the mRNA levels of the Th1 cytokine
IFN-c during the first weeks of infection, which waned towards the
end of the experiment when the infectious process was advanced
(Figure 2A). Immunization with BCG resulted in an earlier, more
intense and sustained expression of IFN-c (Figure 2A). Regarding the
expression of the pro-inflammatory cytokine TNF, non-immunized
mice only revealed a significant increase by day 52 post-infection
(Figure 2B), while BCG-immunized mice showed high mRNA levels
of TNF at earlier time points that were maintained throughout the
experimental period (Figure 2B). Analysis of MIP2 expression revealed
a peak in the mRNA level in the footpads of non-immunized mice at
day 52 post-infection (Figure 2C). In comparison, no significant
differences were observed in BCG-immunized mice over the course of
infection (Figure 2C). The expression of the Th2 cytokine IL-4, the
Th17 cytokine IL-17, as well as of IL-10, was low and did not vary
during infection regardless immunization (Figure S1).
Having observed that the delay in both swelling and bacterial
proliferation in the footpads of BCG-vaccinated mice (Figure 1)
correlated with a Th1 cytokine profile (Figure 2), we next studied
the immunological events taking place in the DLN, where the
initiation of the adaptive immune response against M. ulcerans
occurs [13]. In the DLN of non-immunized mice, infection with
M. ulcerans induced a significant peak in the total number of cells at
day 21 post-infection (Figure 3A), including CD4+ and CD8+ cells
(Figure 3B and C), which later declined with the progression of the
infectious process, as previously described [13]. BCG vaccination
induced a distinct pattern in the DLN cellular dynamics, with an
earlier increase in the numbers of total, CD4+ and CD8+ cells,
levels that were maintained during the experimental infection.
The early appearance of CD4+ T cells in the DLN of BCG-
vaccinated mice prompted us to investigate whether these
Figure 1. Immunization with BCG delays the onset of footpad
swelling and reduces bacillary growth in M. ulcerans infected
mice. Mice were either non-immunized (N) or immunized with BCG
(#) two months before challenge. All mice were infected in the footpad
with 4 log10 CFU of M. ulcerans 98–912. (A) Footpad swelling was
monitored throughout the experimental infection (n=10). The onset of
footpad swelling was considered at 2.60 mm, after which mice
progressed to ulceration of the footpad. For ethical reasons, mice were
sacrificed upon onset of footpad ulceration. (B) Infected footpads of
BCG immunized mice (white bar) or non-immunized mice (black bar)
were harvested at day 52 post-infection and processed for CFU count.
Bars represent the mean 6 SEM (n= 5) log10 CFU/footpad. Statistical
significance was calculated with Student’s t test (***p,0.001).
doi:10.1371/journal.pone.0033406.g001
Transient Vaccine-Induced Protection in Mouse BU
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33406
lymphocytes were able to mount an adaptive effector response. For
this, we followed the kinetics of IFN-c-producing CD4+ cells in the
DLN by intracellular cytokine flow cytometry (Figure 4A), as well
as the mRNA expression of IFN-c (Figure 4B), IL-4, and IL-10
(Figure S2) by real-time PCR. In non-immunized mice, we
observed a significant increase in the IFN-c response in the DLN
at day 21 post-infection, which gradually declined (Figure 4A and
B). In comparison, BCG-vaccinated mice showed an increased
IFN-c response in the DLN as early as 8 days post-infection, a
level which was maintained throughout the experimental infection
(Figure 4A and B). No relevant IL-4 or IL-10 responses were found
in the DLN, as the levels of these cytokines mRNA, in both non-
immunized and BCG-immunized mice, were low and did not vary
throughout the infection period (Figure S2).
Regardless ofM. ulcerans challenge dose, immunizationwith
BCG only confers partial protection, associatedwith a
transientmononuclear infiltratewith activatedmacrophages
Despite the development of an earlier and stronger Th1 response
associated with the initial protection conferred by vaccination, mice
eventually developed footpad swelling (Figure 1), followed by
ulceration (data not shown), indicating that progressive disease was
significantly delayed but not prevented. It has been previously
suggested that high doses of M. ulcerans inocula could compromise
the BCG-induced protection [23]. However, even when a lower
challenge dose of M. ulcerans (2 log10 CFU) was tested, we still
observed that vaccination only conferred partial protection, as
assessed by the emergence of footpad swelling (Figure 5).
This transitory period of protective immunity correlated with a
differential histological pattern in the infected footpads (Figure 6).
We found a strong cellular response in BCG-vaccinated mice
during the first 70 days of M. ulcerans infection (Figure 6B and E),
predominantly consisting of mononuclear cells and granuloma-like
organizations (Figure 6B and E inserts). These areas of
inflammatory infiltrate showed numerous and large foci, positive
for inducible nitric oxide synthase (iNOS) (Figure 7B and E), an
enzyme involved in the production of nitric oxide, which is
necessary for mycobacterial killing [28,29,30]. In accordance,
bacilli were rarely found in the subcutaneous tissue during this
initial period of immune-mediated protection (data not shown).
However, with the progression of the infectious process, the
mononuclear inflammatory infiltrate was later replaced by areas of
Figure 2. BCG vaccination induces an early Th1 cytokine profile inM. ulcerans-infected footpads.Mice were either non-immunized (N) or
immunized with BCG (#) two months before challenge. All mice were infected in the footpad with 4 log10 CFU of M. ulcerans 98–912. At different
times post-infection, total RNA from the footpad was extracted and the presence of mRNA for IFN-a˜ (A), TNF (B), MIP2 (C) was assessed by real-time
PCR. Data points represent the mean 6 SEM (n= 5–8) for each time point. Statistical significance was calculated with Student’s t test (*p,0.05;
**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0033406.g002
Figure 3. Vaccination with BCG induces an early CD4+ T cell response in the DLN of M. ulcerans-infected mice. Mice were either non-
immunized (N) or immunized with BCG (#) two months before challenge. All mice were infected in the footpad with 4 log10 CFU of M. ulcerans 98–
912. At different time points post-infection, the total number of leukocytes in the popliteal lymph node of the infected footpad was counted (A) and
the number of CD4+ (B), and CD8+ (C) cells was determined by flow cytometry. The data points represent the mean 6 SEM (n= 5–8). Statistical
significance was calculated with Student’s t test (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0033406.g003
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subcutaneous tissue damage, extensive necrosis (Figure 6G), and
numerous extracellular bacilli (Figure 6J). Additionally, immuno-
fluorescent staining for iNOS showed sparse positive cells
throughout the tissue (Figure 7G).
In non-immunized infected mice, as previously described [15],
this type of necrotic areas were seen much earlier, as shown at 60
days post-infection (Figure 6A), and expanded progressively into
healthy tissues until day 70 (Figure 6D), when footpad ulceration
emerged (data not shown). A persistent mixed inflammatory
infiltrate was found at the periphery of the necrotic areas,
composed by mononuclear cells and neutrophils (Figure 6A and D
inserts), which were negative for iNOS staining (Figure 7A and D).
These necrotic areas harbored abundant extracellular bacilli
(Figure 6I) and cells with apoptotic morphology (Figure 6D insert).
In addition, histological analysis of DLN from non-immunized
mice revealed that M. ulcerans infection lead to severe structural
damage during the first 70 days of infection, ultimately resulting in
extensive areas of cell death, necrotic alterations, and bacterial
colonization (Figure 8D and I), as recently reported in detail [13].
Conversely, BCG-immunized mice showed no alterations in the
structure of the DLN during these first 70 days (Figure 8B and E).
However, as the infectious process progressed, numerous bacilli
were found along with signs of tissue destruction at 100–125 days
post-infection (Figure 8G and J).
Immunization with mycolactone-negative M. ulcerans
5114 transiently delays the onset of pathology induced
by the highly virulent M. ulcerans strain
It has been suggested that homologous M. ulcerans vaccination
could elicit a more appropriate/prolonged protective immunity
[21,23] than the one induced by BCG vaccination. Therefore, we
decided to test the level of protection conferred by immunization
Figure 4. Vaccination with BCG induces an early IFN-c response in the DLN of M. ulcerans-infected mice. Mice were either non-
immunized (N) or immunized with BCG (#) two months before challenge. All mice were infected in the footpad with 4 log10 CFU of M. ulcerans 98–
912. (A) At different time points post-infection, the total number of CD3+ CD4+ IFN-c+ in the DLN of the infected footpad was determined by flow
cytometry. The data points represent the mean 6 SEM (n= 5–8). (B) At different times post-infection, total RNA from the popliteal lymph node was
extracted and the presence of mRNA for IFN-c was assessed by real-time PCR. Data points represent the mean 6 SEM (n=5–8) for each time point.
Statistical significance was calculated with Student’s t test (*p,0.05). Statistical significance was calculated with Student’s t test (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0033406.g004
Figure 5. Immunization with BCG or mycolactone-negative M. ulcerans delays the onset of footpad swelling after challenge with a
low dose of virulent M. ulcerans. Mice were either non-immunized (N) or immunized with BCG (#) or with M. ulcerans 5114 (n) two months
before challenge. All mice were infected in the footpad with 2 log10 CFU of M. ulcerans 98–912. Footpad swelling was monitored throughout the
experimental infection (n= 10). Initial footpad swelling was considered at 2.60 mm, after which mice progressed to ulceration of the footpad. For
ethical reasons, mice were sacrificed upon onset of footpad ulceration.
doi:10.1371/journal.pone.0033406.g005
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with a live-attenuated M. ulcerans strain. For this, we immunized
mice with the mycolactone-negative strain M. ulcerans 5114,
generated by spontaneous mutation after successive in vitro
passages [25], before challenging mice with 2 log10 of the highly
virulent mycolactone-positive strain. Similar to the findings in
BCG-vaccinated mice, immunization with mycolactone-negative
M. ulcerans induced significant protection against the highly
virulent strain, but failed to permanently prevent disease, with a
median time to develop swelling of 129 days (Figure 5).
The histological analysis of infected footpads of mice vaccinated
with M. ulcerans 5114 revealed scarce infiltrates at day 60 post-
infection (Figure 6C and insert). By day 70 post-infection, a
moderate chronic inflammatory infiltrate was observed (Figure 6F
and insert) along with small foci of iNOS positive cells (Figure 7F).
This infiltrate was eventually replaced by a predominantly
neutrophilic infiltrate, edema, cell death (Figure 6H and insert),
numerous extracellular bacilli (Figure 6K), and characterized by a
loss of iNOS positivity (Figure 7H). As observed in BCG-
vaccinated mice, immunization with strain 5114 resulted in
DLN alterations only after day 70 post-infection (Figure 8H and
I), with bacilli scattered throughout the destroyed lymphoid tissue
(Figure 8J and K).
Discussion
Currently, there is no specific vaccine against M. ulcerans.
However, there is evidence in the literature that suggests the
development of cross-reactive immunity with BCG during M.
ulcerans infections. BCG is a live-attenuated strain of M. bovis used
for the prevention of tuberculosis [31] and leprosy [32]. It has also
been reported that BCG confers some degree of protection against
severe, disseminated manifestations of M. ulcerans infection, namely
osteomyelitis [19,20], but only induces a transient protective
activity against the development of cutaneous lesions. Indeed,
clinical trials confirmed some efficacy of BCG vaccination at
preventing the development of new BU lesions; however, this
Figure 6. Immunization induces a transient mononuclear inflammatory response in the footpad ofM. ulcerans challengedmice.Mice
were either non-immunized (A, D, and I) or immunized with BCG (B, E, G, and J) or with mycolactone-negativeM. ulcerans 5114 (C, F, H, K) two months
before challenge. All mice were infected in the footpad with 2 log10 CFU of M. ulcerans 98–912. The footpads were harvested at on day 60 (A–C), day
70 (D–F and I), or day 150–200 (G–H and J–K) and processed for histology. Tissue sections were stained with HE (A–H) or ZN (I–K). (A, D, and I) Non-
immunized mice showed a persistent mixed inflammatory infiltrate composed of mononuclear cells (arrowheads) and neutrophils (arrows). Necrotic
areas harbored abundant extracellular bacilli (I) and cells with apoptotic morphology (triangles). (B, C, E, F, G, H, J, and K) The footpads of vaccinated
mice presented a mononuclear inflammatory infiltrate (arrowheads) throughout the initial weeks of experimental infection, which was later replaced
by a predominantly neutrophilic infiltrate (arrows) and/or apoptosis (triangles) and extracellular bacilli (J, K). Images are representative of 4 footpads
per group. Original magnification: 106. Original magnification of HE inserts: 1006. Original magnification of ZN: 1006.
doi:10.1371/journal.pone.0033406.g006
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protection waned from 63–72% to nearly zero during the first year
of the study [16,17]. Additionally, studies in the murine model
showed that prior immunization with BCG, or plasmid DNA
encoding Ag85A from BCG, conferred some degree of protection
against experimental M. ulcerans infection, although not sustained
[18,21,22,23,27].
For experimental tuberculosis, it is known that BCG vaccination
induces the generation of protective cellular memory and, upon
subsequent challenge, accelerates the expansion of antigen-specific
T cells, resulting in a significant delay in the establishment of
infection [33]. We have recently shown that CMI is triggered
during M. ulcerans infection. Specifically, early during experimental
murine infection with virulent M. ulcerans, antigen-specific IFN-c-
producing T cells develop in the DLN and differentiated CD4+
cells migrate to the site of infection [13]. However, the subsequent
increase in bacterial burdens and likely mycolactone accumulation
eventually leads to the depletion of the recruited cells and to
extensive destruction of the DLN, abrogating the initially triggered
CMI [13]. Herein, we show that in experimental BU, vaccination
with BCG, although not preventing the eventual emergence of M.
ulcerans disease, significantly delayed its onset through the
induction of an earlier and sustained IFN-c T cell response in
the DLN. In addition, vaccination resulted in increased CMI in M.
ulcerans-infected footpads, as measured by a predominance of a
mononuclear infiltrate, with the activation of macrophages as
shown by areas of iNOS positivity, as well as increased and
sustained levels of IFN-c and TNF, but not IL-4, IL-10 or IL-17.
These responses translated into an improved, albeit transitory,
containment of bacterial proliferation. In line with these findings,
it has been shown that IFN-c, TNF, and iNOS play an important
role in protective immunity against M. ulcerans experimental
infections, contributing to control of bacterial proliferation
[14,28,34]. Additionally, the significant levels of IFN-c observed
in BCG-immunized mice throughout M. ulcerans infection were
associated with a low expression of both IL-4 and IL-17.
Accordingly, it has been reported that IFN-c negatively regulates
the induction of both Th2 [35] and Th17 [36] subsets.
Despite inducing an earlier protective Th1 immune response,
BCG vaccination did not prevent the ultimate progression of
infection with highly virulent M. ulcerans, regardless of challenge
dose. As suggested for tuberculosis, the partial protection
conferred by BCG can be attributed to the fact that the BCG-
induced immune response is quantitatively too weak to elicit
sustained protection against M. ulcerans or, alternatively, is not
Figure 7. Immunization increases iNOS positivity in the footpad of M. ulcerans challenged mice. Mice were either non-immunized (A and
D) or immunized with BCG (B, E, and G) or with mycolactone-negative M. ulcerans 5114 (C, F, and H) two months before challenge. All mice were
infected in the footpad with 2 log10 CFU of M. ulcerans 98–912. The footpads were harvested at on day 60 (A–C), day 70 (D–F), or day 100–200 (G–H
and J–K) and processed for histology. Cells were stained for the presence of iNOS (red) and nuclei were stained with DAPI (blue). In footpads of non-
immunized mice, scarce or no iNOS positive cells were found in the tissue (A, D). The footpads of vaccinated mice presented foci of iNOS positive cells
during the initial weeks of infection (B–C and E–F). With progression of infection, iNOS positivity became sparse. Images are representative of 4
footpads per group. Original magnification: 206.
doi:10.1371/journal.pone.0033406.g007
Transient Vaccine-Induced Protection in Mouse BU
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33406
functionally appropriate to stimulate the type of immune
mechanisms required for persistent protection [37]. In either case,
there would be continuous, although delayed, bacterial prolifer-
ation and mycolactone build-up, leading to the consequent
impairment of protective cellular and molecular mechanisms. In
future studies, it will be important to study later time points of
infection in BCG-vaccinated mice, in order to determine how the
partial protective immunological mechanisms induced by vacci-
nation are compromised.
Species-specific vaccination strategies could also contribute to a
more effective prevention of BU. Given the deficient cross-reactive
immune response elicited by BCG vaccination during M. ulcerans
infection, it has been argued that an M. ulcerans-specific
immunization would be more efficient at controlling infection.
Indeed, there are differences in genetic and antigenic mycobac-
terial composition that can result in variations of immunodomi-
nant epitopes [38]. Therefore, we evaluated the efficacy of a
vaccination protocol with a mycolactone-negative strain of M.
ulcerans. The genetic basis for mycolactone production is related to
a highly unstable giant plasmid required for toxin biosynthesis [39]
and deletion of plasmid sequences leads to a corresponding loss of
toxin production [25]. Mycolactone-negative strains have been
previously generated by spontaneous mutation after repeated in
vitro passages or transposon mutagenesis attenuation [25]. In this
study, we evaluated the efficacy of immunization with a live-
attenuated vaccine based on the 5114 strain of M. ulcerans that lost
the ability to produce mycolactone due to repeated in vitro passages
[24,25]. As for BCG, vaccination with this mycolactone-negative
M. ulcerans only delayed the onset of pathology. This incomplete
protective response may be related to the loss of important
immunogenic epitopes, necessary to stimulate an adequate
protective immune response, due to repeated in vitro passages.
Accordingly, it has been hypothesized that continuous in vitro
passages of M. bovis BCG resulted in deletions of immunodomi-
nant genes and further weakened the vaccine [40]. It is also worth
mentioning that vaccination with another mycolactone-deficient
M. ulcerans strain, genetically inactivated in the polyketide synthase
mlsB gene, can confer sustained protection against M. ulcerans in an
Figure 8. Immunization with BCG or mycolactone-negativeM. ulcerans 5114 delays the destruction of the DLN during infection with
virulentM. ulcerans. Mice were either non-immunized (A, D, and I) or immunized with BCG (B, E, G, and J) or with mycolactone-negative M. ulcerans
5114 (C, F, H, K) two months before challenge. All mice were infected in the footpad with 2 log10 CFU of M. ulcerans 98–912. The DLN were recovered
at day 60 (A–C), day 70 (D–F and I), and days 100–200 (G–H and J–K) and processed for histology. Tissue sections were stained with HE (A–H) or ZN (I–
K). (A, D, and I) In non-immunized mice infection resulted in extensive areas of necrosis and bacterial colonization by day 70 post-infection. (B, C, E, F,
G, H, J, and K) Immunized mice showed no alterations in the structure of the DLN during these first 70 days. As the infectious process progressed in
immunized mice, bacilli could be found throughout the tissue (arrowheads) along with signs of tissue destruction. Images are representative of 4
lymph nodes per group analyzed. Original magnification (A–H): 46. Original magnification (I–K): 1006.
doi:10.1371/journal.pone.0033406.g008
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experimental mouse model (T. Einarsdottir, manuscript in
preparation).
Our data show that BCG induces an immune response capable
of transiently containing M. ulcerans proliferation, but ultimately
fails at preventing the development of disease. Alternative and
improved vaccination strategies could contribute to a more specific
and effective response [38,41]. For instance, the immunogenicity
of conventional BCG or mycolactone-negative M. ulcerans could be
improved by manipulation of its potential to generate protective
immunity by overexpressing immunodominant antigens in
recombinant vaccines, as previously described [42]. An alternative
strategy would be the development subunit vaccines, in which an
immunodominant mycobacterial protein in combination with
appropriate adjuvant or live recombinant viral vector could be
enough to induce sufficient protection. Another approach would
be an anti-toxin based vaccine, since mycolactone has been
described as being largely responsible for the immunopathology of
M. ulcerans disease [1]. Such a vaccine could target either the
biological activity of mycolactone by chemical modification or the
enzymes involved in its synthesis [38]. In addition, it cannot be
excluded that antibody-mediated immunity could also provide
protection against M. ulcerans, with obvious implications for
vaccine development [11,41]. Different studies have detected a
positive specific antibody response against M. ulcerans antigens in
both BU patients and unaffected household contacts, but not in
controls from regions where the disease is not endemic
[43,44,45,46]. Finally, it has also been suggested that inhabitants
of BU endemic areas could be naturally immunized if repeatedly
bitten by uninfected Naucoris cimicoides [47], a protective mecha-
nism suggested for leishmaniasis [48] and Lyme disease [49].
Experimental studies showed that the pre-exposure of mice to
insect salivary antigens rendered mice more resistant to infection
through bites of M. ulcerans harboring-insects. However, the overall
relevance and contribution of biting by M. ulcerans-colonized
insects to the transmission of BU is unknown [50].
Collectively, our results support the perspective that the
development of improved and/or specific vaccine strategies
leading to a stronger and earlier CMI recall immune response
against M. ulcerans, resulting in macrophage activation, before the
build-up of mycolactone compromises T cell persistence, should be
further explored. Moreover, our findings emphasize the impor-
tance of understanding how protective cellular immunity is
compromised by highly virulent M. ulcerans and how the
pathogenic effect could be overcome in order to develop
vaccination strategies for efficient prophylaxis of BU.
Supporting Information
Figure S1 BCG vaccination induces an early Th1
cytokine profile in M. ulcerans-infected footpads. Mice
were either non-immunized (N) or immunized with BCG (#) two
months before challenge. All mice were infected in the footpad
with 4 log10 CFU of M. ulcerans 98–912. At different times post-
infection, total RNA from the footpad was extracted and the
presence of mRNA for IL-4 (A), IL-10 (B), and IL-17 (C) was
assessed by real-time PCR. Data points represent the mean 6
SEM (n= 5–8) for each time point. Statistical significance was
calculated with Student’s t test (*p,0.05; **p,0.01; ***p,0.001).
(TIF)
Figure S2 Vaccination with BCG induces an early Th1
cytokine profile in the DLN of M. ulcerans-infected
mice. Mice were either non-immunized (N) or immunized with
BCG (#) two months before challenge. All mice were infected in
the footpad with 4 log10 CFU of M. ulcerans 98–912. At different
times post-infection, total RNA from the popliteal lymph node was
extracted and the presence of mRNA for IL-4 (A) and IL-10 (B)
was assessed by real-time PCR. Data points represent the mean 6
SEM (n= 5–8) for each time point. Statistical significance was
calculated with Student’s t test (*p,0.05).
(TIF)
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